

Vaccine Adjuvants Market By Type (Immunostimulants, Vehicles and Mucosal Adjuvants), By Disease (Infectious Diseases, Others), By Application (Research, Commercial): Global Opportunity Analysis and Industry Forecast, 2023-2032

Market Report | 2024-02-01 | 280 pages | Allied Market Research

AVAILABLE LICENSES:

- Cloud Access License \$3213.00
- Business User License \$5157.00
- Enterprise License \$8640.00

Report description:

The vaccine adjuvants market was valued at \$1 billion in 2022 and is estimated to reach \$1.5 billion by 2032, exhibiting a CAGR of 4% from 2023 to 2032. Adjuvants are substances that are added to vaccinations in order to strengthen and increase the immune system's reaction to the antigens within the vaccine itself. The components of vaccinations called antigens are what cause the immune system to create antibodies and other immunological responses. Adjuvants assist to increase the efficiency of vaccines by fostering a stronger, longer-lasting, and more robust immune response.

Adjuvants for vaccinations are primarily used to improve an antigen's capacity to elicit an immune response, making it more robust and long-lasting. Adjuvants can accomplish this through a number of strategies, including encouraging immune cell recruitment and activation, boosting immune cell uptake of antigens, and strengthening the immune system's overall identification of the vaccine's components.

Adjuvants enable vaccine manufacturers to employ lower concentrations of antigens, which lowers manufacturing costs and might improve vaccination safety. Furthermore, adjuvants are essential for enhancing the effectiveness of vaccinations, especially when a strong immune response is required, as in the case of elderly patients or those with compromised immune systems. Furthermore, adjuvants for vaccinations are put through extensive testing to make sure they are safe and effective before being added to vaccines. Achieving a balance between boosting the immune response and preserving vaccine safety is the target for the manufacturers and researchers.

The market for vaccine adjuvants is expanding and developing due to a number of causes. The growing need for safer and more effective vaccines is the driving force behind these issues. Vaccine research and development are driven by the increasing prevalence of infectious illnesses and the ongoing efforts to counter new health risks. Adjuvants are becoming more and more necessary to improve the effectiveness of vaccinations as more are being created.

Moreover, global immunization programs are being expanded by various governments globally and also by the international

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

health organizations, which is driving up demand for vaccinations. Adjuvants are critical to the success of large-scale vaccination programs because they enhance the immune response. Also, a rise in the creation of therapeutic vaccines has been attributed to the rising incidence of chronic diseases like cancer. Adjuvants play a crucial role in augmenting the efficacy of these vaccines, hence fueling the vaccine adjuvants market expansion.[]

Moreover, as the population ages, there is a greater chance of developing several diseases. When creating vaccinations for older persons who could have a compromised immune response, adjuvants become more crucial. A further factor driving up demand for adjuvanted vaccinations is this demographic trend.[]

Technological developments in adjuvants and understanding of immune system interactions has improved as a result of developments in immunology and biotechnology. This has aided in the creation of adjuvants that are more focused and effective, spurring market innovation. Both public and private sectors are investing significantly in research and development of vaccines and adjuvants. These investments aim to address unmet medical needs and enhance the overall efficacy and safety profile of vaccines, thus boosting the market growth. []

Regulatory agencies recognizing the importance of vaccine adjuvants in vaccine development provide guidelines and support for their incorporation which increases the adoption of adjuvants. This encourages manufacturers to invest in the development and commercialization of adjuvanted vaccines, which also drives the growth of the market.[]

The vaccine adjuvants market is segmented into type, disease, application, and region. On the basis of type, the market is bifurcated into immunostimulants and vehicles and[]mucosal adjuvants. The []immunostimulants segment is further segmented into toll like receptor and others. As per disease, the market is divided into infectious diseases and cancer. The infectious diseases segment market is further segregated into hepatitis and others. On the basis of application, the market is classified into research and commercial.[]

Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and the rest of Europe), Asia-Pacific (India, China, Japan, Australia, South Korea, and rest of Asia-Pacific), and Latin America (Brazil, Argentina, Colombia and rest of Latin America) and Middle East and Africa (GCC, South Africa, North Africa, and rest of LAMEA).[]

The major players that operate in the vaccine adjuvants market include Adjuvatis, Dynavax Technologies Corporation, GSK, Croda International, Novovax, SEPPIC, Agenesis Inc, Invivogen, SPI Pharma, and Aurorium. These key players have adopted key strategies such as partnership and business expansion to expand their product portfolio.[]

Key Benefits for Stakeholders

- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the vaccine adjuvants market analysis from 2022 to 2032 to identify the prevailing vaccine adjuvants market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the vaccine adjuvants market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global vaccine adjuvants market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

working days of free work, applicable once)

- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

- Regulatory Guidelines
- Strategic Recommendations
- Additional company profiles with specific to client's interest
- Additional country or region analysis- market size and forecast
- Expanded list for Company Profiles
- Historic market data
- SWOT Analysis

Key Market Segments

By Type

- Immunostimulants
- Type
- Toll-like receptor
- Others
- Vehicles and Mucosal Adjuvants

By Disease

- Infectious Diseases
- Type
- Hepatitis
- Others
- Others

By Application

- Research
- Commercial

By Region

- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Colombia
- Argentina
- Rest of Latin America
- Middle East and Africa
- Gcc
- South Africa
- North Africa
- Rest of Middle East And Africa
- Key Market Players
- Dynavax Technologies Corporation
- Novovax
- Agenus Inc.
- Adjuvatis
- Aurorium
- InvivoGen
- SEPPIC
- GlaxoSmithKline plc
- SPI Pharma, Inc.
- Croda International Plc

Table of Contents:

CHAPTER 1: INTRODUCTION

- 1.1. Report description
- 1.2. Key market segments
- 1.3. Key benefits to the stakeholders
- 1.4. Research methodology
 - 1.4.1. Primary research
 - 1.4.2. Secondary research
 - 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

- 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

- 3.1. Market definition and scope
- 3.2. Key findings
 - 3.2.1. Top impacting factors
 - 3.2.2. Top investment pockets
- 3.3. Porter's five forces analysis
- 3.4. Market dynamics
 - 3.4.1. Drivers
 - 3.4.2. Restraints
 - 3.4.3. Opportunities

CHAPTER 4: VACCINE ADJUVANTS MARKET, BY TYPE

- 4.1. Overview

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 4.1.1. Market size and forecast
- 4.2. Immunostimulants
 - 4.2.1. Key market trends, growth factors and opportunities
 - 4.2.2. Market size and forecast, by region
 - 4.2.3. Market share analysis by country
 - 4.2.4. Immunostimulants Vaccine Adjuvants Market by Type
- 4.3. Vehicles and Mucosal Adjuvants
 - 4.3.1. Key market trends, growth factors and opportunities
 - 4.3.2. Market size and forecast, by region
 - 4.3.3. Market share analysis by country

CHAPTER 5: VACCINE ADJUVANTS MARKET, BY DISEASE

- 5.1. Overview
 - 5.1.1. Market size and forecast
- 5.2. Infectious Diseases
 - 5.2.1. Key market trends, growth factors and opportunities
 - 5.2.2. Market size and forecast, by region
 - 5.2.3. Market share analysis by country
 - 5.2.4. Infectious Diseases Vaccine Adjuvants Market by Type
- 5.3. Others
 - 5.3.1. Key market trends, growth factors and opportunities
 - 5.3.2. Market size and forecast, by region
 - 5.3.3. Market share analysis by country

CHAPTER 6: VACCINE ADJUVANTS MARKET, BY APPLICATION

- 6.1. Overview
 - 6.1.1. Market size and forecast
- 6.2. Research
 - 6.2.1. Key market trends, growth factors and opportunities
 - 6.2.2. Market size and forecast, by region
 - 6.2.3. Market share analysis by country
- 6.3. Commercial
 - 6.3.1. Key market trends, growth factors and opportunities
 - 6.3.2. Market size and forecast, by region
 - 6.3.3. Market share analysis by country

CHAPTER 7: VACCINE ADJUVANTS MARKET, BY REGION

- 7.1. Overview
 - 7.1.1. Market size and forecast By Region
- 7.2. North America
 - 7.2.1. Key market trends, growth factors and opportunities
 - 7.2.2. Market size and forecast, by Type
 - 7.2.3. Market size and forecast, by Disease
 - 7.2.4. Market size and forecast, by Application
 - 7.2.5. Market size and forecast, by country
 - 7.2.5.1. U.S.
 - 7.2.5.1.1. Market size and forecast, by Type
 - 7.2.5.1.2. Market size and forecast, by Disease
 - 7.2.5.1.3. Market size and forecast, by Application
 - 7.2.5.2. Canada

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 7.2.5.2.1. Market size and forecast, by Type
- 7.2.5.2.2. Market size and forecast, by Disease
- 7.2.5.2.3. Market size and forecast, by Application
- 7.2.5.3. Mexico
 - 7.2.5.3.1. Market size and forecast, by Type
 - 7.2.5.3.2. Market size and forecast, by Disease
 - 7.2.5.3.3. Market size and forecast, by Application
- 7.3. Europe
 - 7.3.1. Key market trends, growth factors and opportunities
 - 7.3.2. Market size and forecast, by Type
 - 7.3.3. Market size and forecast, by Disease
 - 7.3.4. Market size and forecast, by Application
 - 7.3.5. Market size and forecast, by country
 - 7.3.5.1. Germany
 - 7.3.5.1.1. Market size and forecast, by Type
 - 7.3.5.1.2. Market size and forecast, by Disease
 - 7.3.5.1.3. Market size and forecast, by Application
 - 7.3.5.2. France
 - 7.3.5.2.1. Market size and forecast, by Type
 - 7.3.5.2.2. Market size and forecast, by Disease
 - 7.3.5.2.3. Market size and forecast, by Application
 - 7.3.5.3. UK
 - 7.3.5.3.1. Market size and forecast, by Type
 - 7.3.5.3.2. Market size and forecast, by Disease
 - 7.3.5.3.3. Market size and forecast, by Application
 - 7.3.5.4. Italy
 - 7.3.5.4.1. Market size and forecast, by Type
 - 7.3.5.4.2. Market size and forecast, by Disease
 - 7.3.5.4.3. Market size and forecast, by Application
 - 7.3.5.5. Spain
 - 7.3.5.5.1. Market size and forecast, by Type
 - 7.3.5.5.2. Market size and forecast, by Disease
 - 7.3.5.5.3. Market size and forecast, by Application
 - 7.3.5.6. Rest of Europe
 - 7.3.5.6.1. Market size and forecast, by Type
 - 7.3.5.6.2. Market size and forecast, by Disease
 - 7.3.5.6.3. Market size and forecast, by Application
- 7.4. Asia-Pacific
 - 7.4.1. Key market trends, growth factors and opportunities
 - 7.4.2. Market size and forecast, by Type
 - 7.4.3. Market size and forecast, by Disease
 - 7.4.4. Market size and forecast, by Application
 - 7.4.5. Market size and forecast, by country
 - 7.4.5.1. Japan
 - 7.4.5.1.1. Market size and forecast, by Type
 - 7.4.5.1.2. Market size and forecast, by Disease
 - 7.4.5.1.3. Market size and forecast, by Application

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 7.4.5.2. China
 - 7.4.5.2.1. Market size and forecast, by Type
 - 7.4.5.2.2. Market size and forecast, by Disease
 - 7.4.5.2.3. Market size and forecast, by Application
- 7.4.5.3. India
 - 7.4.5.3.1. Market size and forecast, by Type
 - 7.4.5.3.2. Market size and forecast, by Disease
 - 7.4.5.3.3. Market size and forecast, by Application
- 7.4.5.4. Australia
 - 7.4.5.4.1. Market size and forecast, by Type
 - 7.4.5.4.2. Market size and forecast, by Disease
 - 7.4.5.4.3. Market size and forecast, by Application
- 7.4.5.5. South Korea
 - 7.4.5.5.1. Market size and forecast, by Type
 - 7.4.5.5.2. Market size and forecast, by Disease
 - 7.4.5.5.3. Market size and forecast, by Application
- 7.4.5.6. Rest of Asia-Pacific
 - 7.4.5.6.1. Market size and forecast, by Type
 - 7.4.5.6.2. Market size and forecast, by Disease
 - 7.4.5.6.3. Market size and forecast, by Application
- 7.5. Latin America
 - 7.5.1. Key market trends, growth factors and opportunities
 - 7.5.2. Market size and forecast, by Type
 - 7.5.3. Market size and forecast, by Disease
 - 7.5.4. Market size and forecast, by Application
 - 7.5.5. Market size and forecast, by country
 - 7.5.5.1. Brazil
 - 7.5.5.1.1. Market size and forecast, by Type
 - 7.5.5.1.2. Market size and forecast, by Disease
 - 7.5.5.1.3. Market size and forecast, by Application
 - 7.5.5.2. Colombia
 - 7.5.5.2.1. Market size and forecast, by Type
 - 7.5.5.2.2. Market size and forecast, by Disease
 - 7.5.5.2.3. Market size and forecast, by Application
 - 7.5.5.3. Argentina
 - 7.5.5.3.1. Market size and forecast, by Type
 - 7.5.5.3.2. Market size and forecast, by Disease
 - 7.5.5.3.3. Market size and forecast, by Application
 - 7.5.5.4. Rest of Latin America
 - 7.5.5.4.1. Market size and forecast, by Type
 - 7.5.5.4.2. Market size and forecast, by Disease
 - 7.5.5.4.3. Market size and forecast, by Application
- 7.6. Middle East and Africa
 - 7.6.1. Key market trends, growth factors and opportunities
 - 7.6.2. Market size and forecast, by Type
 - 7.6.3. Market size and forecast, by Disease
 - 7.6.4. Market size and forecast, by Application

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 7.6.5. Market size and forecast, by country
 - 7.6.5.1. Gcc
 - 7.6.5.1.1. Market size and forecast, by Type
 - 7.6.5.1.2. Market size and forecast, by Disease
 - 7.6.5.1.3. Market size and forecast, by Application
 - 7.6.5.2. South Africa
 - 7.6.5.2.1. Market size and forecast, by Type
 - 7.6.5.2.2. Market size and forecast, by Disease
 - 7.6.5.2.3. Market size and forecast, by Application
 - 7.6.5.3. North Africa
 - 7.6.5.3.1. Market size and forecast, by Type
 - 7.6.5.3.2. Market size and forecast, by Disease
 - 7.6.5.3.3. Market size and forecast, by Application
 - 7.6.5.4. Rest of Middle East And Africa
 - 7.6.5.4.1. Market size and forecast, by Type
 - 7.6.5.4.2. Market size and forecast, by Disease
 - 7.6.5.4.3. Market size and forecast, by Application

CHAPTER 8: COMPETITIVE LANDSCAPE

- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product mapping of top 10 player
- 8.4. Competitive dashboard
- 8.5. Competitive heatmap
- 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

- 9.1. Dynavax Technologies Corporation
 - 9.1.1. Company overview
 - 9.1.2. Key executives
 - 9.1.3. Company snapshot
 - 9.1.4. Operating business segments
 - 9.1.5. Product portfolio
 - 9.1.6. Business performance
 - 9.1.7. Key strategic moves and developments
- 9.2. Novovax
 - 9.2.1. Company overview
 - 9.2.2. Key executives
 - 9.2.3. Company snapshot
 - 9.2.4. Operating business segments
 - 9.2.5. Product portfolio
 - 9.2.6. Business performance
- 9.3. SEPPIC
 - 9.3.1. Company overview
 - 9.3.2. Key executives
 - 9.3.3. Company snapshot
- 9.4. Agenus Inc.
 - 9.4.1. Company overview
 - 9.4.2. Key executives

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
- 9.4.6. Business performance
- 9.4.7. Key strategic moves and developments
- 9.5. Aurorium
 - 9.5.1. Company overview
 - 9.5.2. Key executives
 - 9.5.3. Company snapshot
 - 9.5.4. Operating business segments
 - 9.5.5. Product portfolio
- 9.6. Adjuvatis
 - 9.6.1. Company overview
 - 9.6.2. Key executives
 - 9.6.3. Company snapshot
 - 9.6.4. Operating business segments
 - 9.6.5. Product portfolio
- 9.7. InvivoGen
 - 9.7.1. Company overview
 - 9.7.2. Key executives
 - 9.7.3. Company snapshot
- 9.8. GlaxoSmithKline plc
 - 9.8.1. Company overview
 - 9.8.2. Key executives
 - 9.8.3. Company snapshot
 - 9.8.4. Operating business segments
 - 9.8.5. Product portfolio
 - 9.8.6. Business performance
 - 9.8.7. Key strategic moves and developments
- 9.9. SPI Pharma, Inc.
 - 9.9.1. Company overview
 - 9.9.2. Key executives
 - 9.9.3. Company snapshot
- 9.10. Croda International Plc
 - 9.10.1. Company overview
 - 9.10.2. Key executives
 - 9.10.3. Company snapshot

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Vaccine Adjuvants Market By Type (Immunostimulants, Vehicles and Mucosal Adjuvants), By Disease (Infectious Diseases, Others), By Application (Research, Commercial): Global Opportunity Analysis and Industry Forecast, 2023-2032

Market Report | 2024-02-01 | 280 pages | Allied Market Research

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Cloud Access License	\$3213.00
	Business User License	\$5157.00
	Enterprise License	\$8640.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐ ** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	2025-05-06

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Signature

A large, empty rectangular box with a thin black border, intended for a signature.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com